Armata Pharmaceuticals stock rises on FDA breakthrough designation

Armata Pharmaceuticals (NYSE American: ARMP) reported Q2 2026 results for the quarter ended June 30, 2026, with $2.5M grant and award revenue, R&D of about $7.6M, G&A of about $5.2M, and an operating loss of about $10.3M. The company said it submitted the Phase 3 protocol for AP-SA02 to the FDA, received Fast Track and an agreed pediatric study plan, and received an additional $2.5M non-dilutive DoD funding.

Armata Pharmaceuticals, Inc. (ARMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update ​ LOS ANGELES, Calif., August 12, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnolo

Armata Pharmaceuticals said it submitted the complete Phase 3 protocol for its AP-SA02 multi-phage therapy to the FDA, addressing End-of-Phase 2 feedback, and completed four engineering runs at its Los Angeles cGMP facility. The Phase 3 superiority study is planned to start in 2H 2026. The company received a $2.5M DoD continuation award. ARMP shares were up 10.27% to $4.97.

Armata Pharmaceuticals (ARMP) said the U.S. FDA agreed to its Initial Pediatric Study Plan for AP-SA02 in pediatric complicated Staphylococcus aureus bacteremia. The iPSP sets a framework to defer pediatric work until adult Phase 3 data, expected to start in H2 2026, then run a single multicenter open-label pediatric trial. ARMP shares closed July 10 at $4.26.

Warner Music Group and Sony Music sued AI company Anthropic, alleging it pirated thousands of songs to train its models. The lawsuit, filed in California, seeks up to $150,000 per infringed work and $25,000 per copyright removal. Anthropic, valued at $2 trillion, previously settled a similar lawsuit for $1.5 billion. The music groups also referenced a 2024 class-action lawsuit against Anthropic by authors.

Scholar Rock Holding Corp (SRRK) stock rose 9.1% to $60.45 after the FDA approved its drug ISEMBYLD for spinal muscular atrophy. Analysts raised price targets, with Truist Securities at $76, Raymond James at $72, and Citi at $74, citing strong revenue potential. The company has $492 million in cash and is ready to commercialize the drug.